Minimal Residual Disease (MRD) was initially proposed in blood disorders, which refers to the presence of trace amounts of malignant tumor cells in the body during the disease remission (CR) after clinical treatment. These cells may cause the relapse of hematological malignancies.

An MRD test looks for any cancer cells that were not killed by chemotherapy or other cancer treatments. MRD is a measure used for multiple myeloma, lymphoma, leukemia, and other blood cancers.

MEDx HemeMRD kit is used to quantitatively (relatively quantitatively) detect the rearrangement of human B lymphocyte antigen receptor (BCR) gene. For patients with acute B lymphoblastic leukemia (B-ALL), multiple myeloma (MM), and chronic lymphoblastic leukemia (CLL), the CDR3 sequence of BCR gene is amplified by multiplex PCR and analyzed by NGS during the initial diagnosis to screen out the dominant tumor clonal sequences. During the treatment, the patient samples were regularly monitored for the load level of clonal sequences to assist drug efficacy evaluation, relapse monitoring, and clone evolution tracking.

Advantages of HEME-MRD Detection

o     High sensitivity: Sensitivity as high as 0.0001%

o     Broad applicationss: Suitable for B-ALL, MM and CLL patients

o   Detection of new clones: Identifications of clone evolutions, immune recovery, and immune reconstitution

o     Excellent repeatability: Standardarized  experimental process and bioinformatics analysis

Indications of HEME-MRD Detection

Sample Requirementsand Sensitivity